ALBIREO PHARMA, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $40.6M | $8.3M | $9.6M | $12.7M | $1,000 | — |
| Operating income | −$123.5M | −$96.3M | −$61.1M | −$37.9M | −$24.6M | −$12.3M |
| Net income | −$34.0M | −$107.6M | −$62.7M | −$46.1M | −$24.4M | −$16.4M |
| Total assets | $302.1M | $285.6M | $165.1M | $185.5M | $73.2M | $49.7M |
| Total liabilities | $126.4M | $104.4M | $71.9M | $62.8M | $8.0M | $12.7M |
| Equity | $175.6M | $181.2M | $93.2M | $122.6M | $65.3M | $37.0M |
| EPS (diluted) | $-1.77 | $-6.73 | — | — | — | — |
| Shares out. | 19.1M | 14.9M | 12.0M | 11.9M | 6.3M | 6.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −304.3%
- Net margin
- −83.9%
- Return on equity
- −19.4%
- Return on assets
- −11.3%
- Return on capital (ROCE)
- −48.1%
- Liabilities / assets
- 41.9%
- Debt / equity
- 0.72×
- Book value / share
- $9.19
- Revenue growth (YoY)
- 388.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- 0.32distress
- Accruals / assets
- 24.3%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 19, 2018
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Chiswell DavidDirector | Mar 2, 2023 | U | 56,278 | — |
| Harford Simon N.R.Officer — CFO and Treasurer | Mar 2, 2023 | U | 13,739 | — |
| Cooper Ronald Harold WilfredOfficer — President and CEO | Mar 2, 2023 | U | 33,094 | — |
| Stephenson PamelaOfficer — Chief Commercial Officer | Mar 2, 2023 | U | 22,242 | — |
| Graham MichelleOfficer — Chief Human Resources Officer | Mar 2, 2023 | U | 5,543 | — |
| Carter Martha J.Officer — Chief Regulatory Officer | Mar 2, 2023 | U | 3,656 | — |
| Duncan JasonOfficer — Chief Legal Officer and GC | Mar 2, 2023 | U | 3,296 | — |
| Mattsson JanOfficer — Chief Scientific Officer | Mar 2, 2023 | U | 35,524 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 2, 2023
- Other material eventFeb 14, 2023
- Entered a material agreement · Regulation FD disclosureJan 9, 2023
- Director / officer change · Regulation FD disclosureDec 6, 2022
- Results of operationsNov 8, 2022
- Results of operations · Other material eventOct 11, 2022
- Entered a material agreement · Regulation FD disclosureSep 22, 2022
- Entered a material agreement · Terminated a material agreementAug 16, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2024
- SC 13G/AApr 10, 2023
- 15-12GMar 14, 2023
- EFFECTMar 8, 2023
- EFFECTMar 8, 2023
- EFFECTMar 8, 2023
- EFFECTMar 8, 2023
- EFFECTMar 8, 2023
- SC 13G/AMar 8, 2023
- 4FORM 4 SUBMISSIONMar 3, 2023
- 4FORM 4 SUBMISSIONMar 2, 2023
- 4FORM 4 SUBMISSIONMar 2, 2023
- 4FORM 4 SUBMISSIONMar 2, 2023
- 4FORM 4 SUBMISSIONMar 2, 2023
- 4FORM 4 SUBMISSIONMar 2, 2023